Press release
Asia Pacific SGLT2 Inhibitors Market Size, Growth Rate, and Competitive Landscape: 2025-2034 | AstraZeneca, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company
Asia Pacific SGLT2 Inhibitors Market
๐๐๐ฉ๐จ๐ซ๐ญ ๐๐๐จ๐ฉ๐:
This comprehensive study provides an accurate overview of the worldwide Asia Pacific SGLT2 inhibitors market. Comprehensive analyses of sales volume, price, revenue, market share, and important companies are included. The market is further divided into segments by indication, drug, distribution channel, and country in the study, which offers a comprehensive picture of the state of the market.
๐๐๐ญ ๐๐ฑ๐๐ฅ๐ฎ๐ฌ๐ข๐ฏ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ ๐๐ฌ ๐จ๐ ๐๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ:
https://www.polarismarketresearch.com/industry-analysis/asia-pacific-sglt2-inhibitors-market/request-for-sample
๐๐๐ซ๐ค๐๐ญ ๐๐๐๐ข๐ง๐ข๐ญ๐ข๐จ๐ง:
SGLT2 inhibitors (Sodium-Glucose Cotransporter 2 inhibitors) are a group of drugs mainly used to manage type 2 diabetes. They function by inhibiting the SGLT2 protein in the kidneys. This stops glucose from being reabsorbed into the bloodstream and encourages glucose elimination in the urine, reducing blood sugar levels. SGLT2 inhibitors additionally provide advantages in treating heart failure and chronic kidney disease by decreasing fluid retention and enhancing cardiovascular results.
๐๐ซ๐ข๐ฏ๐๐ซ๐ฌ ๐๐ง๐ ๐๐ซ๐๐ง๐๐ฌ:
โข The increasing occurrence of type 2 diabetes in the Asia Pacific, spurred by urban development, lifestyle shifts, and genetic factors, is boosting the need for efficient diabetes management options such as SGLT2 Inhibitors.
โข Rapid urbanization in the Asia Pacific region has caused significant transformations in eating patterns. A growing number of individuals are transitioning from traditional, whole-food diets to calorie-dense, processed foods. This movement, combined with a less active lifestyle, has contributed to the rise in obesity rates, a key risk factor for developing type 2 diabetes.
๐๐จ๐ฉ ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ:
In this extremely competitive market, major rivals constantly innovate and differentiate their products in an effort to take the lead in the market. Here are the top companies in the
Asia Pacific SGLT2 inhibitors market:
โข AstraZeneca
โข Boehringer Ingelheim International GmbH
โข Bristol-Myers Squibb Company
โข Eli Lilly and Company
โข Glenmark Pharmaceuticals Ltd.
โข Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
โข Lexicon Pharmaceuticals, Inc.
โข Merck & Co., Inc.
โข Sanofi
๐๐๐ช๐ฎ๐๐ฌ๐ญ ๐๐จ๐ซ ๐ ๐๐ข๐ฌ๐๐จ๐ฎ๐ง๐ญ ๐จ๐ง ๐ญ๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐๐๐จ๐ซ๐ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐: https://www.polarismarketresearch.com/industry-analysis/asia-pacific-sglt2-inhibitors-market/request-for-discount-pricing
๐๐จ๐ฎ๐ง๐ญ๐ซ๐ฒ-๐๐ข๐ฌ๐ ๐๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ:
โข North America (U.S., Canada)
โข Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
โข Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
โข Latin America (Brazil, Mexico, Argentina)
โข Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)
๐๐๐ ๐ฆ๐๐ง๐ญ๐๐ฅ ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค:
The market is mainly segmented based on indication, drug, distribution channel, and country. Based on indication analysis, the type 2 diabetes segment held the largest market share in 2024. The prevalence of type 2 diabetes is rising in the Asia Pacific region, resulting in a considerable need for efficient diabetes management strategies.
According to distribution channel analysis, the hospital pharmacies segment is anticipated to witness the fastest growth from 2025 to 2034. The growing prevalence of type 2 diabetes has resulted in more hospitalizations for diabetes-related complications, such as cardiovascular problems, kidney issues, and diabetic.
๐๐ง๐ช๐ฎ๐ข๐ซ๐ ๐ฆ๐จ๐ซ๐ ๐๐๐จ๐ฎ๐ญ ๐ญ๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐๐๐จ๐ซ๐ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐: https://www.polarismarketresearch.com/industry-analysis/asia-pacific-sglt2-inhibitors-market/inquire-before-buying
๐๐๐ฒ ๐๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ ๐จ๐ ๐๐ฌ๐ข๐ ๐๐๐๐ข๐๐ข๐ ๐๐๐๐๐ ๐๐ง๐ก๐ข๐๐ข๐ญ๐จ๐ซ๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฉ๐จ๐ซ๐ญ:
โข Based on indication, the type 2 diabetes segment accounted for the largest revenue share in 2023. The rising number of type 2 diabetes cases in Asia Pacific due to changing lifestyles, urbanization, and dietary habits is driving significant demand for effective diabetes management solutions, including SGLT2 inhibitors.
โข Based on distribution channel, the hospital pharmacies segment is projected to register the fastest growth from 2024 to 2032. With the increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer, there is a growing need for comprehensive and continuous medical care. Hospital pharmacies play a crucial role in managing these conditions by providing necessary medications and ensuring proper drug administration.
โข In 2023, China accounted for the largest market share in the Asia Pacific SGLT2 inhibitors market due to government initiatives, healthcare reforms, and heightened research and development efforts focused on diabetes management.
โข AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi, Pfizer Inc.; Lupin; and Cipla limited. are a few of the key players in the market.
๐๐๐ฅ๐๐ญ๐๐ ๐๐๐ฉ๐จ๐ซ๐ญ:
๐๐๐๐๐ ๐๐ง๐ก๐ข๐๐ข๐ญ๐จ๐ซ๐ฌ ๐๐๐ซ๐ค๐๐ญ
https://www.polarismarketresearch.com/industry-analysis/sglt2-inhibitors-market
๐๐ข๐ฌ๐ฉ๐จ๐ฌ๐๐๐ฅ๐ ๐๐ง๐๐จ๐ฌ๐๐จ๐ฉ๐๐ฌ ๐๐๐ซ๐ค๐๐ญ
https://www.polarismarketresearch.com/industry-analysis/disposable-endoscopes-market
๐๐ซ๐ฎ๐ ๐๐๐ฏ๐ข๐๐ ๐๐จ๐ฆ๐๐ข๐ง๐๐ญ๐ข๐จ๐ง ๐๐ซ๐จ๐๐ฎ๐๐ญ๐ฌ ๐๐๐ซ๐ค๐๐ญ
https://www.polarismarketresearch.com/industry-analysis/drug-device-combination-products-market
๐๐ซ๐๐๐ฌ๐ญ ๐๐๐ง๐๐๐ซ ๐๐ข๐ช๐ฎ๐ข๐ ๐๐ข๐จ๐ฉ๐ฌ๐ฒ ๐๐๐ซ๐ค๐๐ญ
https://www.polarismarketresearch.com/industry-analysis/breast-cancer-liquid-biopsy-market
๐๐๐ฅ๐๐ซ๐๐๐ข๐จ๐ฅ๐จ๐ ๐ฒ ๐๐จ๐๐ญ๐ฐ๐๐ซ๐ ๐๐๐ซ๐ค๐๐ญ
https://www.polarismarketresearch.com/industry-analysis/teleradiology-software-market
Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter
About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Asia Pacific SGLT2 Inhibitors Market Size, Growth Rate, and Competitive Landscape: 2025-2034 | AstraZeneca, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company here
News-ID: 3805493 • Views: โฆ
More Releases from Polaris Market Research & Consulting
Granite Market Projected to Reach USD 6.63 Billion by 2034, Growing at a CAGR of โฆ
Polaris Market Research has released new insights into the Granite market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors.
Market at a Glance
In 2024, the market was valued at USD 3.99 billion and is anticipated to grow to USD 6.63 Billion by 2034. Itโฆ
Molecular Diagnostics for Sexually Transmitted Diseases Market to Reach USD 7.85 โฆ
Polaris Market Research announces the release of its latest study on the Molecular Diagnostics For Sexually Transmitted Diseases market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 3.82 billion in 2024 and is expected toโฆ
Higher Alpha Olefins Market Projected to Hit USD 20.01 Billion by 2034, Expandin โฆ
Polaris Market Research announces the release of its latest study on the Higher Alpha Olefins market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 10.39 billion in 2024 and is expected to reach 20.01 billionโฆ
Direct Oral Anticoagulants (DOACs) Device Market to Reach USD 64.83 Billion by 2 โฆ
Polaris Market Research announces the release of its latest study on the Direct Oral Anticoagulants (DOACs) Device market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape.
According to the findings, the market stood at 31.67 billion in 2024 and is expected to reachโฆ
More Releases for Asia
Asia Private Equity Firm, Asia Private Equity Management, Asia Private Equity Se โฆ
The private equity market in China has been rapidly growing in recent years. Private equity (PE) refers to the purchase of shares in a company that are not publicly traded on a stock exchange. PE firms typically target companies that are undervalued or in need of capital for growth, and aim to improve the company's operations and financial performance before selling it at a higher value.
https://boomingfaucet.com/
Asia Private Equity Consulting
E-mail:nolan@pandacuads.com
In China,โฆ
South East Asia Business Jet Market And Top Key Players are Asia Corporate Jet, โฆ
By 2022, the South East Asia Business Jet Markets estimated to reach US$ XX Mn, up from US$ XX Mn in 2016, growing at a CAGR of XX% during the forecast period. The Global Business Jet Market, currently at 21 million USD, contributes the highest share in the market and is poised to grow at the fastest rate in the future. The three broad categories of business jets are Small,โฆ
LIXIL Asia Presents Asia Pacific Property Awards
Through its power brands GROHE and American Standard, LIXIL Asia signs a three-year deal to become the Headline Sponsor of the Asia Pacific Property Awards from 2019 until 2022.
23rd January 2019: The International Property Awards, first established in 1993, are open to residential and commercial property professionals from around the globe. They celebrate the highest levels of achievement by companies operating within the architecture, interior design, real estate and propertyโฆ
PEOPLEWAVE WINS ASIA TECH PODCAST PITCHDECK ASIA 2019 AWARDS
15 January 2019, Singapore โ Peoplewave, Asiaโs leading data-driven HR technology company, won the Asia Tech Podcast (ATP) Pitchdeck Asia 2019 Awards, being awarded โStartup Most Likely to Succeed in 2019".
The 2019 Pitchdeck Asia Awards is an opportunity for the Asian Startup Ecosystem to shine a spotlight on some of its best startups. The awards were decided by a public vote. More than 7,200 votes were cast by registered LinkedInโฆ
Undersea Defence Technology Asia, UDT Asia 2011
Latest Military Diving Technologies featured in UDT Asia
Equipping Asiaโs navies with the latest diving technology for asymmetric warfare and
operations
SINGAPORE, 17 October 2011 - Naval diving and underwater special operations is a field that is
seeing increased attention and investment amongst navies in Asia. Units such as the Indonesian Navyโs KOPASKA, the Republic of Singapore Navyโs Naval Diving Unit (NDU), the Royal Malaysian Navyโs PASKAL are increasingly utilising specialised equipment for conductingโฆ
Asia Diligence โ Specialist Investigative Due Diligence for Asia & Beyond
Asia Diligence today announced the opening of its European Customer Services office in the United Kingdom. The office is to be managed by Steve Fowler and will focus on providing services to Asia Diligenceโs European customers. Asia Diligence is also planning to open a US office in the near future, which will provide customer service to its US and North American clients.
Asked to comment on the move, Luke Palmer, theโฆ
